TopiVert Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Out of Business

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Out of Business

TopiVert General Information

Description

Developer of medical inhibition technologies designed to treat chronic inflammatory diseases of the gastrointestinal tract and the eyes. The company's technologies are used for the treatment of ulcerative colitis to deliver strong data with an oral formulation and medication consistently to the colon at pharmacologically relevant concentrations, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 71 Kingsway
  • London WC2B 6ST
  • England, United Kingdom
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Vertical(s)
Corporate Office
  • 71 Kingsway
  • London WC2B 6ST
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TopiVert Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Out of Business 18-Jan-2021 Completed Out of Business
5. Later Stage VC 01-Jun-2018 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series A2) 15-Apr-2016 Completed Pre-Clinical Trials
3. Early Stage VC (Series A2) 29-Sep-2014 Completed Pre-Clinical Trials
2. Early Stage VC (Series A2) 31-Aug-2012 $12.6M $12.6M Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Startup
To view TopiVert’s complete valuation and funding history, request access »

TopiVert Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A2
To view TopiVert’s complete cap table history, request access »

TopiVert Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of medical inhibition technologies designed to treat chronic inflammatory diseases of the gastrointestinal tra
Biotechnology
London, United Kingdom
11 As of 2016

Vienna, Austria
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TopiVert Competitors (36)

One of TopiVert’s 36 competitors is CSL Behring (Biotechnology), a Corporation company based in Vienna, Austria.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CSL Behring (Biotechnology) Corporation Vienna, Austria
Genentech Formerly VC-backed South San Francisco, CA
Renova Therapeutics Venture Capital-Backed Carlsbad, CA
CSL Behring Corporation King Of Prussia, PA
Lexeo Therapeutics Formerly VC-backed New York, NY
You’re viewing 5 of 36 competitors. Get the full list »

TopiVert Patents

TopiVert Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3015978-A1 Kinase inhibitors Inactive 06-Apr-2016
WO-2017174995-A1 Kinase inhibitors Inactive 06-Apr-2016
ES-2840650-T3 4,5,6,7-tetrahydro-1h-imidazo [4,5-c] pyridine and 1,4,5,6,7,8-hexahydroimidazo [4,5-d] azepine derivatives as kinase inhibitors janus Active 03-Nov-2015
ES-2864035-T3 4,5,6,7-tetrahydro-1h-imidazo [4,5-c] pyridine and 1,4,5,6,7,8-hexahydroimidazo [4,5-d] azepine derivatives as kinase inhibitors janus Active 03-Nov-2015
CA-3037248-A1 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors Inactive 03-Nov-2015 C07D471/04
To view TopiVert’s complete patent history, request access »

TopiVert Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TopiVert FAQs

  • When was TopiVert founded?

    TopiVert was founded in 2010.

  • Where is TopiVert headquartered?

    TopiVert is headquartered in London, United Kingdom.

  • What is the size of TopiVert?

    TopiVert has 11 total employees.

  • What industry is TopiVert in?

    TopiVert’s primary industry is Biotechnology.

  • Is TopiVert a private or public company?

    TopiVert is a Private company.

  • What is TopiVert’s current revenue?

    The current revenue for TopiVert is .

  • How much funding has TopiVert raised over time?

    TopiVert has raised $37.7M.

  • Who are TopiVert’s competitors?

    CSL Behring (Biotechnology), Genentech, Renova Therapeutics, CSL Behring, and Lexeo Therapeutics are some of the 36 competitors of TopiVert.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process